An important recommendation from the AASLD Guidelines

Important recommendation from the AASLD Guidelines video thumbnail (swatch)
Important recommendation from the AASLD Guidelines video thumbnail (resize)  

Dr. Arun Jesudian

Assistant Professor of Medicine and Director of Inpatient Liver Services

Weill Cornell Medicine, New York, New York

Watch Dr. Jesudian discuss some of the AASLD Guidelines for managing overt HE with XIFAXAN.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.